Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIMILAR Trial: Santeon Infliximab Biosimilar Research
2015-001954-14Phase 4Active
- Sponsor
- Santeon
- Start
- Aug 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of infliximab in Crohn's disease and autoimmune colitis (2 arms), sponsored by Santeon. Primary endpoint: Relapse rate. Started Aug 2015; status: active.
02
Drugs
infliximab
03
Conditions
Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on 2015-001954-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001954-14.